Holen Sie sich die Stockscreener-App
118.45
2.62%
-3.16
Schlusskurs vom Vortag:
$121.61
Offen:
$119.92
24-Stunden-Volumen:
345.21K
Relative Volume:
0.22
Marktkapitalisierung:
$10.66B
Einnahmen:
$2.24B
Nettoeinkommen (Verlust:
$385.90M
KGV:
31.76
EPS:
3.73
Netto-Cashflow:
$440.10M
1W Leistung:
+11.10%
1M Leistung:
+35.28%
6M Leistung:
-5.82%
1J Leistung:
-14.82%
1-Tages-Spanne:
$117.53
$120.00
1-Wochen-Bereich:
$107.96
$130.46
52-Wochen-Spanne:
$84.23
$157.98
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Firmenname
Neurocrine Biosciences Inc
Sektor
Telefon
(858) 617-7600
Adresse
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Vergleichen Sie NBIX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
118.39 | 10.66B | 2.24B | 385.90M | 440.10M | 3.73 |
|
ZTS
Zoetis Inc
|
160.44 | 69.76B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.30 | 48.12B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.75 | 45.75B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.09 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
303.55 | 13.67B | 2.76B | 1.11B | 898.10M | 22.77 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-15 | Hochstufung | Needham | Hold → Buy |
| 2025-04-14 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Hold |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-08-29 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | Fortgesetzt | Citigroup | Neutral |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-08-21 | Bestätigt | Mizuho | Neutral |
| 2023-07-24 | Hochstufung | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-03-30 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-02-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-10-11 | Eingeleitet | UBS | Buy |
| 2022-09-26 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-06-06 | Fortgesetzt | Jefferies | Buy |
| 2022-03-03 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | Hochstufung | Goldman | Neutral → Buy |
| 2022-01-18 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Underperform |
| 2021-11-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-10-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Fortgesetzt | Needham | Hold |
| 2021-08-06 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | Fortgesetzt | Goldman | Neutral |
| 2021-05-06 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-02-02 | Eingeleitet | Raymond James | Outperform |
| 2020-09-30 | Eingeleitet | The Benchmark Company | Hold |
| 2020-08-04 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-06-29 | Herabstufung | Goldman | Buy → Neutral |
| 2020-06-09 | Eingeleitet | Wedbush | Outperform |
| 2020-03-06 | Eingeleitet | Citigroup | Buy |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-24 | Eingeleitet | William Blair | Outperform |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2020-02-05 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-13 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-07-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-05 | Eingeleitet | Guggenheim | Neutral |
| 2019-05-21 | Eingeleitet | Credit Suisse | Outperform |
| 2019-04-22 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-02-06 | Bestätigt | BofA/Merrill | Buy |
| 2019-01-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-12-13 | Eingeleitet | Goldman | Buy |
| 2018-11-21 | Eingeleitet | Canaccord Genuity | Buy |
Alle ansehen
Neurocrine Biosciences Inc Aktie (NBIX) Neueste Nachrichten
Neurocrine Reports Late Stage Data Of Crenessity - marketscreener.com
Neurocrine Biosciences Announces New Results from Exploratory Analyses of the Phase 3 CAHtalyst™ Pediatric Study Demonstrating CRENESSITY™ Reduces Glucocorticoid Dosing While Maintaining or Improving Androstenedione Across Patient Subgrou - PR Newswire
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q1 2025 Earnings Call Transcript - Insider Monkey
Neurocrine Biosciences, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now - simplywall.st
Why Neurocrine Biosciences, Inc. (NBIX) Skyrocketed On Tuesday - Insider Monkey
Neurocrine Bio stock target raised at Needham following earnings By Investing.com - Investing.com Canada
RBC Capital lifts Neurocrine Bio. stock target to $145 on sales momentum - Investing.com Nigeria
Neurocrine Biosciences (NBIX) Receives Price Target Raise from C - GuruFocus
Neurocrine Biosciences’ Earnings Call Highlights Growth Amid Challenges - TipRanks
NBIX: Analyst BMO Capital Raises Price Target for Neurocrine Bio - GuruFocus
Neurocrine Biosciences to Present at Upcoming Investor Conferences in May - PR Newswire
Guggenheim Ups Price Target for Neurocrine (NBIX) Amid Ingrezza Sales Performance | NBIX Stock News - GuruFocus
Neurocrine Biosciences (NBIX) Price Target Raised by RBC Capital | NBIX Stock News - GuruFocus
Neurocrine Biosciences Stock Price, Quotes and Forecasts | NASDAQ:NBIX - Benzinga
Neurocrine Biosciences' Ingrezza Q1 Sales Prove Resilient, Analysts Boost Price Target - Benzinga
Cantor Fitzgerald maintains Overweight on Neurocrine Bio, $170 target - Investing.com
Cantor Fitzgerald maintains Overweight on Neurocrine Bio, $170 target By Investing.com - Investing.com India
Neurocrine Biosciences Surges On 'Surprising' Momentum For Its Newest Drug - inkl
NBIX: Analyst BMO Capital Raises Price Target for Neurocrine Biosciences | NBIX Stock News - GuruFocus
Neurocrine Biosciences (NBIX) Target Price Raised by UBS Analyst | NBIX Stock News - GuruFocus
Wedbush Boosts Neurocrine (NBIX) Price Target Following Strong R - GuruFocus
BofA Securities Adjusts Price Target on Neurocrine Biosciences to $183 From $179, Maintains Buy Rating - marketscreener.com
Wedbush Boosts Neurocrine (NBIX) Price Target Following Strong Results | NBIX Stock News - GuruFocus
Neurocrine Bio stock target raised at Needham following earnings - Investing.com
RBC Capital Increases Price Target for Neurocrine (NBIX) to $145 | NBIX Stock News - GuruFocus
Neurocrine Biosciences and Carnie Wilson Team Up to Launch ConnectING with Carnie™ Awareness Campaign for People with Tardive Dyskinesia - Nasdaq
UBS Elevates Neurocrine (NBIX) Price Target and Highlights Growth Prospects | NBIX Stock News - GuruFocus
Neurocrine (NBIX) Sees Price Target Adjustment Amid Strong Earni - GuruFocus
RBC Raises Price Target on Neurocrine Biosciences to $145 From $137, Keeps Outperform Rating - marketscreener.com
Neurocrine Biosciences (NBIX) Receives Price Target Raise from Canaccord Genuity | NBIX Stock News - GuruFocus
What 19 Analyst Ratings Have To Say About Neurocrine Biosciences - Benzinga
Analyst Maintains Buy Rating on Neurocrine Biosciences (NBIX) with Raised Price Target | NBIX Stock News - GuruFocus
Neurocrine (NBIX) Sees Price Target Increased Following Strong Q1 Performance | NBIX Stock News - GuruFocus
S&P 500 Futures Drop in Premarket Trading; Neurocrine Biosciences, Regal Rexnord Lead - Barron's
Neurocrine Biosciences (NBIX) Price Target Increased by Canaccor - GuruFocus
Palantir, Ford, Tesla, Constellation Energy, Clorox, Hims & Hers, Neurocrine, AMD, and More Movers - Barron's
Neurocrine Biosciences (NBIX) Price Target Increased by Canaccord | NBIX Stock News - GuruFocus
Neurocrine (NBIX) Sees Price Target Adjustment Amid Strong Earnings Report | NBIX Stock News - GuruFocus
Palantir, Ford, Tesla, Clorox, Hims & Hers, Neurocrine, AMD, and More Market Movers - Barron's
Neurocrine Biosciences Inc (NBIX) Q1 2025 Earnings Call Highlights: Strong INGREZZA Sales and ... By GuruFocus - Investing.com Canada
Neurocrine Biosciences Reports Strong Q1 2025 Results - TipRanks
Neurocrine: Q1 Earnings Snapshot - The Washington Post
Earnings call transcript: Neurocrine Biosciences Q1 2025 results miss EPS expectations - Investing.com Nigeria
Neurocrine Biosciences (NBIX) Surges 13% After Strong Q1 Results - GuruFocus
Neurocrine surges 13% on Q1 revenue beat, reaffirmed 2025 guidance - Seeking Alpha
Neurocrine (NBIX) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
Neurocrine Biosciences (NBIX) Q1 Earnings Miss Estimates - Yahoo Finance
Neurocrine Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Neurocrine Biosciences stock soars on strong INGREZZA guidance By Investing.com - Investing.com South Africa
Neurocrine Biosciences stock soars on strong INGREZZA guidance - Investing.com
NBIX Reports Strong Q1 Revenue and Reaffirms Sales Guidance | NBIX Stock News - GuruFocus
Finanzdaten der Neurocrine Biosciences Inc-Aktie (NBIX)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.53%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):